Rtw Investments Adds $4M in Evommune, Inc. ($EVMN)
RTW Investments increased its Evommune holdings by 17%, adding 218,564 shares.
Key Points
- RTW Investments boosted its stake in Evommune, Inc. by 17%, adding 218,564 shares to reach a total of 1,502,235 shares valued at $29.79 million as of its latest 13F filing.
- Evommune, Inc. trades on the NYSE under the ticker EVMN, with a market cap of approximately $714.2 million and a 52-week range between $13.89 and $33.20.
- Analysts are optimistic about Evommune with HC Wainwright & Co. and Morgan Stanley maintaining 'buy' ratings, reflecting strong support for the biotech firm's outlook.
RTW Investments boosted its stake in Evommune, Inc. (NYSE:EVMN) by 17%, adding 218,564 shares to hold a total of 1,502,235 shares. The position is now valued at approximately $29.79 million, according to the latest Form 13F filing with the SEC, reflecting holdings as of the reporting period.
What Changed in RTW Investments' Evommune Position
RTW Investments increased its holdings in Evommune, Inc. from 1,283,671 shares to 1,502,235 shares, marking a change of 218,564 shares or 17%. This boost brings the total value of RTW's position to about $29.79 million, signaling a strengthened commitment to the biotechnology company.
Other Institutional Activity in Evommune
Among Evommune's other institutional investors, EQT Fund Management S.A R.L. maintained its position with 4,929,633 shares valued at approximately $113.33 million. RA Capital Management, L.P. added 35,868 shares, ending with 3,494,638 shares worth roughly $80.34 million. JPMorgan Chase & Co also grew its holdings by 150,519 shares, bringing its total to 1,459,420 shares valued at around $32.11 million.
Evommune, Inc. Stock Snapshot
Shares of NYSE:EVMN traded near $19.83. Evommune has a market cap of about $714.2 million. The stock's 52-week low is $13.89, and its high is $33.20. The 50-day moving average is $23.74, while the 200-day moving average is $22.02. The company has a strong current ratio of 20.36 and a quick ratio of 19.94, with a debt-to-equity ratio of 2.99.
Recent Earnings
Evommune, Inc. reported revenue of $10 million, with no net margin due to its clinical-stage operations. The company posted an EPS of -2.11, and its return on equity was -44.95%. Evommune is set to release its next earnings on August 6, 2026.
Analysts Set New Price Targets
On May 26, 2026, HC Wainwright & Co. reiterated its 'buy' rating with a $50 price target. Earlier, on May 11, Morgan Stanley maintained a 'buy' rating, setting a target at $55. RBC Capital also reiterated a 'buy' rating with a $48 target on April 10. The consensus among analysts is a 'strong buy' with a mean target price of $52.25 based on 8 opinions.
About Evommune, Inc.
Evommune, Inc. is a clinical-stage biotechnology company based in Palo Alto, California. It focuses on developing therapies for chronic inflammatory diseases, such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its lead products include EVO756 and EVO301, targeting these conditions. Founded in 2020, the company is led by CEO Luis C. Pena and employs 48 people.
Bottom Line
RTW Investments' increased stake in Evommune, Inc. reflects a growing interest in the biotech firm's potential. Investors and analysts are keeping a close watch on Evommune's progress, especially given its focus on innovative therapies for chronic inflammatory diseases. As always, 13F filings are backward-looking and may not represent current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.